134 related articles for article (PubMed ID: 37897252)
1. Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification.
Ferro M; Rocco B; Maggi M; Lucarelli G; Falagario UG; Del Giudice F; Crocetto F; Barone B; La Civita E; Lasorsa F; Brescia A; Catellani M; Busetto GM; Tataru OS; Terracciano D
Expert Rev Mol Diagn; 2023; 23(12):1061-1070. PubMed ID: 37897252
[TBL] [Abstract][Full Text] [Related]
2. Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy.
Busetto GM; Del Giudice F; Maggi M; De Marco F; Porreca A; Sperduti I; Magliocca FM; Salciccia S; Chung BI; De Berardinis E; Sciarra A
World J Urol; 2021 Jun; 39(6):1869-1877. PubMed ID: 32681273
[TBL] [Abstract][Full Text] [Related]
3. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
Hendriks RJ; van der Leest MMG; Dijkstra S; Barentsz JO; Van Criekinge W; Hulsbergen-van de Kaa CA; Schalken JA; Mulders PFA; van Oort IM
Prostate; 2017 Oct; 77(14):1401-1407. PubMed ID: 28853167
[TBL] [Abstract][Full Text] [Related]
4. Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.
Wysock JS; Becher E; Persily J; Loeb S; Lepor H
Urology; 2020 Jul; 141():119-124. PubMed ID: 32294481
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric MRI
Pepe P; Dibenedetto G; Pepe L; Pennisi M
In Vivo; 2020; 34(1):393-396. PubMed ID: 31882504
[TBL] [Abstract][Full Text] [Related]
6. A SelectMDx/magnetic resonance imaging-based nomogram to diagnose prostate cancer.
Wagaskar VG; Levy M; Ratnani P; Sullimada S; Gerenia M; Schlussel K; Choudhury S; Gabriele M; Haas I; Haines K; Tewari A
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1668. PubMed ID: 36168681
[TBL] [Abstract][Full Text] [Related]
7. SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study.
Maggi M; Del Giudice F; Falagario UG; Cocci A; Russo GI; Di Mauro M; Sepe GS; Galasso F; Leonardi R; Iacona G; Carroll PR; Cooperberg MR; Porreca A; Ferro M; Lucarelli G; Terracciano D; Cormio L; Carrieri G; De Berardinis E; Sciarra A; Busetto GM
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922626
[TBL] [Abstract][Full Text] [Related]
8. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
[TBL] [Abstract][Full Text] [Related]
9. Combination of PI-RADS score and mRNA urine test-A novel scoring system for improved detection of prostate cancer.
Katzendorn O; von Klot CAJ; Mahjoub S; Faraj Tabrizi P; Harke NN; Tezval H; Hellms S; Hennenlotter J; Baig MS; Stenzl A; Seith F; Lafos M; Kuczyk MA; Rausch S; Peters I
PLoS One; 2022; 17(8):e0271981. PubMed ID: 35960727
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer.
Visser WCH; de Jong H; Steyaert S; Melchers WJG; Mulders PFA; Schalken JA
Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):583-589. PubMed ID: 35810263
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men.
Hendriks RJ; van der Leest MMG; Israël B; Hannink G; YantiSetiasti A; Cornel EB; Hulsbergen-van de Kaa CA; Klaver OS; Sedelaar JPM; Van Criekinge W; de Jong H; Mulders PFA; Crawford ED; Veltman J; Schalken JA; Barentsz JO; van Oort IM
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1110-1119. PubMed ID: 33941866
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of trans-rectal color doppler flow imaging and risk-stratification nomogram reduce unnecessary prostate biopsies in suspected prostate cancer patients: a bi-centered retrospective validation study.
Guo Y; Su K; Lu M; Liu X
BMC Urol; 2023 May; 23(1):81. PubMed ID: 37138271
[TBL] [Abstract][Full Text] [Related]
14. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
[TBL] [Abstract][Full Text] [Related]
15. Can the predictive value of multiparametric MRI for prostate cancer be improved by a liquid biopsy with SelectMDx?
Rahnama'i MS; Bach C; Schulze-Hagen M; Kuhl CK; Vögeli TA
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1396. PubMed ID: 33931984
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer.
Stabile A; Dell'Oglio P; Soligo M; De Cobelli F; Gandaglia G; Fossati N; Esposito A; Brembilla G; Karnes RJ; Montorsi F; Briganti A
Eur Urol Oncol; 2021 Aug; 4(4):594-600. PubMed ID: 31204312
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naïve patients with clinical suspicion of prostate cancer who underwent the Select MDx test.
Lendínez-Cano G; Ojeda-Claro AV; Gómez-Gómez E; Morales Jimenez P; Flores Martin J; Dominguez JF; Amores J; Cozar JM; Bachiller J; Juárez A; Linares R; Garcia Galisteo E; Alvarez Ossorio JL; Requena Tapia MJ; Moreno Jimenez J; Medina Lopez RA;
Prostate; 2021 Sep; 81(12):857-865. PubMed ID: 34184761
[TBL] [Abstract][Full Text] [Related]
18. Prediction of clinically significant prostate cancer after negative prostate biopsy: The current value of microscopic findings.
Morote J; Schwartzman I; Borque A; Esteban LM; Celma A; Roche S; de Torres IM; Mast R; Semidey ME; Regis L; Santamaría A; Planas J; Trilla E
Urol Oncol; 2021 Jul; 39(7):432.e11-432.e19. PubMed ID: 33160846
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis.
Sari Motlagh R; Yanagisawa T; Kawada T; Laukhtina E; Rajwa P; Aydh A; König F; Pallauf M; Huebner NA; Baltzer PA; Karakiewicz PI; Heidenreich A; Shariat SF
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):187-198. PubMed ID: 35414118
[TBL] [Abstract][Full Text] [Related]
20. Nomogram predicting prostate cancer in patients with negative prebiopsy multiparametric magnetic resonance.
Chen M; Wang R; Zhang T; Zhang X; Wan Y; Fu X
Future Oncol; 2022 Apr; 18(12):1473-1483. PubMed ID: 35105154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
